Chemed Corporation

Chemed's 21.6 P/E sits meaningfully above the typical home health care operator despite solid fundamentals, suggesting the market is pricing in accelerating growth or margin expansion. The RSI of 65.1 indicates building momentum without extreme overbought conditions, while the modest 3.81% short float leaves minimal squeeze potential. Trading below its 52-week high provides some cushion, yet the valuation premium relative to peers warrants scrutiny—particularly if demographic tailwinds (aging population) don't fully materialize or competitive pressures intensify. The current setup feels fairly valued for quality but leaves limited margin of safety for near-term disappointments.